NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global pulmonary arterial hypertension (PAH) drugs market size is estimated to grow by USD 2.26 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 6.78% during the forecast period. Growing prevalence of pah is driving market growth, with a trend towards increasing awareness regarding PAH.
However, high costs associated with pah treatment poses a challenge.Key market players include Aerami Therapeutics Holdings Inc., Aerovate Therapeutics Inc.
, Alembic Pharmaceuticals Ltd., Asklepion Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Daiichi Sankyo Co. Ltd.
, Dr Reddys Laboratories Ltd., Eiger BioPharmaceuticals Inc., Gilead Sciences Inc.
, GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co.
Inc., Novartis AG, Pfizer Inc., Reata Pharmaceuticals Inc.
, Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., and Viatris Inc.
. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver Pulmonary Arterial Hypertension (PAH) is a rare and progressive disorder characterized by high blood pressure in the pulmonary arteries, which transport blood from the heart to the lungs.
This condition occurs when pulmonary arteries narrow or become blocked, leading to increased pressure in the pulmonary arterial system. The prevalence of PAH has risen .
